LONDON, July 1, 2026 /PRNewswire/ -- FxPro, the #1 global broker, has announced a massive overhaul of its trading conditions, completely eliminating spreads on major cryptocurrency and index CFDs.
By driving spreads down to absolute zero on Bitcoin, Ethereum and more, FxPro is delivering institutional-grade pricing to the retail market, setting a new benchmark for competitive trading conditions. Crucially, these zero spreads are backed by deep liquidity, meaning traders can access them not just with minimum trade sizes but also when executing high-volume orders.
Zero Spreads on Bitcoin, Ethereum, Dow & Nasdaq100
Traders can now execute positions with no markup whatsoever, backed by a highly transparent, low-commission structure.
These changes establish FxPro as the most compelling broker for active traders seeking institutional-style pricing, powerful execution and high, flexible leverage.
"By bringing spreads down to zero on our flagship Raw+ account, we are directly responding to the trading community's demand for ultra-low-cost market access," said Jakub Soltys, Head of Execution at FxPro. "We are removing friction so traders can focus purely on market opportunity with institutional-style pricing."
Clients can access these newly optimised 0 spread conditions across multiple award-winning platforms, including MT4, MT5, and the 5-star rated FxPro App with the Raw+ account type, depending on their jurisdiction.
Huge Spread Reductions on Standard Accounts
Major spread reductions of nearly 80% have also been applied to FxPro Standard accounts, ensuring significantly improved pricing is accessible across all account tiers and jurisdictions.
About FxPro
FxPro is the world's #1 broker with over 145 awards and is trusted by millions of clients worldwide. For over two decades, the company has provided access to over 2,100 trading instruments across FX, stocks, futures, indices, metals, energy and more via its powerful platforms. Regulated across multiple jurisdictions, FxPro delivers ultra-fast execution, deep liquidity and a client-centric trading experience.
Media Contact:
PR@fxpro.com
www.fxpro.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
FxPro Eliminates Spread on Cryptos & Indices
Leading Companies Present Science-Backed Solutions Addressing Antimicrobial Resistance, Digestive Health, and Wellness Through Advanced Probiotics and Clinical Botanicals
BANGKOK, July 1, 2026 /PRNewswire/ -- As global healthcare confronts the urgent challenge of antimicrobial resistance, Vitafoods Asia 2026, the region's premier nutraceutical trade show organised by Informa Markets, will showcase pioneering solutions that blend scientific rigour with natural innovation. Leading this charge are LiveSpo and Natural Remedies, two industry innovators presenting breakthrough technologies that address critical health burdens through advanced probiotics and clinical botanicals.
From the world's first probiotic nasal spray to next-generation botanical ingredients delivering unprecedented efficacy at minimal doses, these companies demonstrate how evidence-based natural solutions can reduce antibiotic dependence while supporting digestive health, respiratory wellness, and immunity. Their innovations represent the convergence of traditional wisdom and modern science, offering effective, sustainable alternatives to conventional treatments for global populations facing pressing health challenges.
LiveSpo: Pioneering a Future Without Antibiotics
LiveSpo, a biotechnology leader specialising in spore-based probiotics, is introducing world-first innovations that could transform how healthcare approaches antibiotic usage. The company is the first and only manufacturer globally to successfully produce high-quality, multi-species spore probiotics in liquid form, enabling clinically validated products across multiple applications.
At the forefront of LiveSpo's innovations is LiveSpo NAVAX, the world's first probiotic nasal spray designed to support respiratory health. Clinical trials demonstrate that NAVAX shortens RSV infection symptoms by one day and influenza symptoms by one to two days while increasing treatment effectiveness by 10–60% compared with physiological saline. The formulation reduces pro-inflammatory cytokines up to 3.6-fold more effectively in RSV cases and shortens pneumonia symptom duration by one day with 20–90% improved treatment efficacy.
LiveSpo's digestive health portfolio addresses the global burden of digestive disorders, which cause approximately 1.8 million deaths annually, with over 80% occurring in children under five years. LiveSpo Clausy, LiveSpo Colon, and LiveSpo Dia30 have been clinically shown to reduce antibiotic treatment duration by up to 25% when used alongside standard therapy and shorten persistent diarrhoea treatment by approximately three days. These formulations provide two-fold greater improvement in IBD-related symptom severity compared with control groups.
LiveSpo Kids specifically targets paediatric digestive wellness, demonstrating five-fold improvement in constipation management and eleven-fold enhancement in appetite compared to standard treatments. Clinical studies show the formulation increases weight by 0.3 kg per month in growing children while reducing pro-inflammatory cytokine IL-23 concentration nine-fold and increasing IgA ten-fold by day 28.
LiveSpo's unique spore probiotic technology provides 24-month stability in zone 4B with no cold storage required, ensuring product quality regardless of shipping route—a critical advantage for global distribution.
"I always believe that the most important thing for a scientist is how their research is applied in real life, how it can benefit and serve the community," said Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo. "Every year, there are about 5 million deaths worldwide caused by antibiotic resistance, mostly among children under 5 years old. The World Health Organisation has repeatedly warned about the global issue of drug resistance, but until now, WHO has not provided an effective tool to replace antibiotics. In 2013, LiveSpo Pharma successfully researched and developed the technology for producing Liquid Form, Multi-strains, High Concentration Spore Probiotics, which have the potential to gradually replace antibiotics."
He further added, "Vitafoods Asia provides the ideal platform for us to showcase our advanced spore probiotic technology to reputable partners across the region. As we pursue strategic regional expansion, this event allows us to connect with key industry players who share our vision of delivering innovative, science-backed probiotic solutions. We're eager to demonstrate how our pioneering liquid spore probiotic technology can help partners address critical health challenges while supporting our mission toward a future without antibiotics"
Natural Remedies: Transforming Nature into Clinical Excellence
Natural Remedies – Human Health Care brings decades of botanical expertise combined with cutting-edge science to Vitafoods Asia 2026. The company is showcasing its portfolio of clinically researched, standardised herbal ingredients designed for the global nutraceutical market.
The spotlight innovation is Ashwa.30™, a next-generation Ashwagandha ingredient powered by proprietary B.O.T™ (Bioactive Optimisation Technology). This breakthrough delivers benefits for energy, endurance, longevity, and stress management at just 30 mg per day, redefining efficacy in low-dose botanical supplementation.
Natural Remedies' comprehensive portfolio of clinically validated ingredients addresses multiple health categories. Holixer® is an award-winning ingredient clinically shown to provide better sleep experience, while BacoMind® enhances memory, focus, and recall. Gutgard® offers daily support for optimal digestive health, and Turmacin® provides water-soluble turmeric for superior joint health. The company's AP-Bio® / Kalmcold® offers trusted immune support solutions.
All ingredients combine traditional wisdom with rigorous scientific validation, featuring clinically proven efficacy, standardised bioactive profiles, low effective dosages, and global regulatory readiness. Products are registered with TGA, ANVISA, and KFDA, and comply with USA and EU standards, ensuring premium quality and trust worldwide. The company maintains ISO-certified R&D facilities and conducts rigorous clinical trials while practising responsible sourcing, biodiversity conservation, and greener energy solutions.
"The future of wellness lies in botanicals that combine traditional wisdom with modern scientific validation," said Dr. Suresh, Chief Business Officer, Natural Remedies. "Through innovations like B.O.T Technology, we are enabling the next generation of high-performance, science-backed botanical solutions."
He further added, "As a global leader in science-backed botanical ingredients, we see Vitafoods Asia as an essential trade event for connecting with partners and industry leaders who are shaping the future of health and wellness. This year, we're excited to showcase our latest innovations and demonstrate how clinically validated botanicals can empower brands to create truly differentiated, evidence-based products that meet evolving consumer demands for natural, effective health solutions."
Both companies serve nutraceutical, dietary supplement, functional food, beverage, and pharmaceutical sectors, with particular strength in active longevity and healthy ageing, stress and sleep management, cognitive performance, digestive and metabolic health, sports nutrition, immune support, and respiratory wellness.
For more information about Vitafoods Asia 2026, visit www.vitafoodsasia.com
About Vitafoods Asia
Vitafoods Asia is the leading nutraceutical event in Asia, bringing together industry professionals from across the globe to explore the latest trends, innovations, and opportunities in the nutraceutical and functional food sectors.
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.
For media inquiries, please contact:
Gautam Jatwani
Senior Marketing Manager
Gautam.jatwani@informa.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
Vitafoods Asia 2026: Science-Backed Botanicals and Next-Generation Probiotics Take Centre Stage
